corvas
international
said
initiated
phase
ia
clinical
trial
assess
safety
effects
anticoagulant
recombinant
napc2
trial
primarily
demonstrate
safety
demonstrate
feasibility
adminstering
compound
subcutaneously
anticoagulant
effects
increasing
dosage
levels
duration
compound
bloodstream
following
administration
randall
woods
corvas
president
chief
executive
officer
said
statement.napc2
designed
treat
deep
vein
thrombosis
occurs
complication
orthopedic
surgery
lead
formation
blood
clots
major
veins
leg
